Fluidigm to Develop and Supply a Custom High-throughput Prep System for HLA Typing
News May 03, 2013
Fluidigm announced an agreement to develop and supply a customized version of its high- throughput library prep system to the DKMS (Deutsche Knochenmarkspenderdatei gemeinnützige Gesellschaft mbH) Life Science Lab. The new system will help the DKMS accelerate its research to fight against blood cancer by ultimately enabling it to characterize the HLA genes from several thousand samples a week for its donor registry. The Fluidigm custom Access Array™ System, currently under development, will seamlessly automate library preparation for next-generation sequencing (NGS) with a new integrated fluidic circuit (IFC) that will greatly increase sample throughput. This new format specifically addresses the sample throughput and quality requirements demanded by DKMS, while meeting the complexity of library prep for HLA typing. The DKMS expects to go live with the new Access Array System in the fall of this year.
The DKMS is focused on finding stem cell donors for patients with blood cancer and other severe blood diseases. The objective of HLA testing is to determine the degree of tissue compatibility between transplant recipients and donors. The higher the number of HLA matches, the lower the risk of rejection following transplantation. Given the diversity of the HLA system, allele-specific approaches are required for donor-recipient matching. The custom high-throughput Access Array System and NGS will enhance the DKMS’s capability for high-resolution HLA typing at a fraction of the cost of conventional sequence-based typing.
“The DKMS is very excited about the opportunities arising through the application of NGS for HLA typing,” reported Dr. Alexander Schmidt, Scientific Director. “Taking advantage of Fluidigm’s technologies, we have successfully established a fast and lean NGS workflow. We are very much looking forward to the new Access Array format that will increase the amazing throughput even further!”
“This project demonstrates Fluidigm’s willingness to develop enabling, customized solutions that address bottlenecks for research performed in high-throughput clinical labs,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “The work that the DKMS does is critical in the fight against leukemia. Fluidigm is proud to be part of the fight.”
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
Multi-tissue, Multi-individual Data Used to Identify Mechanisms of Gene RegulationNews
Developing a mechanistic model for how healthy bodies function and how certain diseases merge may now be possible.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018